Oncoscience GmbH develops therapeutic options for rare diseases in oncology. Despite intensive research in oncology, the needs of adequate treatment of these orphan diseases often cannot be met by major pharmaceutical companies.

Currently Oncoscience as part of Innokeys Pte Ltd accomplishes the clinical development of Nimotuzumab for Europe. Nimotuzumab is a monoclonal antibody that can be used for the treatment of several malignancies. Nimotuzumab has the status as orphan drug both in the US and Europe for diffuse intrinsic pontine glioma and pancreatic cancer.